tbuckley/cabot-search huggingface dataset:
Concerns Regarding Opicapone as Adjunct to Levodopa Therapy–Reply
Authors: Andrew J. Lees, José-Francisco Rocha, Patricio Soares-da-Silva
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) for males with HCG-expressing, chemorefractory germ cell tumors (GCT): Long-term efficacy and safety outcomes.
Authors: Daniele Raggi, Patrizia Giannatempo, Rosalba Miceli, Elena Farè, Nicola Nicolai, Luigi Piva, Davide Biasoni, Mario Catanzaro, Tullio Torelli, Silvia Stagni, Manuela Marongiu, Alessandro M. Gianni, Roberto Salvioni, Andrea Necchi
Journal: Journal of Clinical Oncology (2014)

4561 Background: Patients (pts) with GCT who fail to be cured following multiple chemotherapy (CT) courses (including high-dose CT) have an extremely poor prognosis. EMA/CO regimen has shown efficacy in high-risk gestational trophoblastic tumors. Since 1992 we introduced this regimen for human chorionic gonadotropin (HCG)-producing refractory GCT. Methods: We retrieved data of adult male pts who received methotrexate (MTX) 100 mg/m2 followed by MTX 200 mg/m2 over 12h d1, etoposide 100 mg/m2 and dactinomycin 0.5 mg mg/m2 d1-2, folinic acid 15 mg orally every 6h d2-3, followed by cyclophosphamide 600 mg/m2 plus vincristine 1 mg/m2 d8, every 21 days. Treatment was continued until marker normalization. Pts had a HCG+ GCT and had failed at least 2 CT regimens. Multivariable analysis (MVA) was undertaken to analyze candidate prognostic factors. ITT analysis was applied. Results: From 02/92 to 05/13, 41 pts were treated in 3rd (20, 49%) or >3rd line (21, 51%). 36 (88%) had a mixed GCT, 2 a pure seminoma and 3 a clinical diagnosis. 7 (17%) had an extragonadal primary, 17 (41%) had liver, bone, or brain (LBB) metastases, and 21 (51%) HCG>1000 IU/l. 16 (39%) had received HDCT. 33 pts (80.5%) had a response with marker reduction, including 5 complete (12.2%) and 7 (17.1%) partial responses (PR) with HCG normalization. After a median follow up of 98 months (IQR: 80-183), 6 pts did not relapsed and 6 were alive. Median progression-free survival was 3 months (95%CI, 2-4) and median overall survival was 8 months (95%CI, 6-10). On MVA, the line of treatment (>3rd vs 3rd) was the only significant predictor of both PFS (HR: 2.50, 95%CI, 1.20-5.24, p=0.015) and OS (HR: 3.17, 95%CI: 1.46-6.89, p=0.004). Overall 16 pts (39%) had G3-4 hematologic and 1 pt mucositis and gastrointestinal toxicity each. No discontinuations for toxicity occurred.1 toxic death (cerebral hemorrhage) occurred. Conclusions: EMA/CO is an active regimen with acceptable toxicity and could be considered an option for the subset of HCG+ chemoresistant GCT having failed multiple lines, including pts who are not candidate to salvage HDCT.
Lack of Evidence for Benefit From Long-term Use of Opioid Analgesics for Patients With Neuropathy
Authors: Nora D. Volkow, Walter Koroshetz
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient
Authors: Richard W. Peck
Journal: The Annual Review of Pharmacology and Toxicology (2017)

Genomics has helped to initiate the era of precision medicine, with some drugs now prescribed on the basis of molecular genetic tests that indicate which patients are likely to respond or should not receive a drug because of a high risk of adverse effects. However, for precision medicine to realize its potential, the patient's history, environment, and lifestyle must also be taken into account. Improving precision medicine requires a better understanding of the underlying reasons for the variability in drug response so as to better identify which drug or combination of drugs is likely to be most effective for an individual patient, along with consideration of the optimal dose or doses for that patient. Greater individualization of dose will be an important means to achieve more precise medicine and mitigate significant variability in drug response. Achieving this will require changes in how drugs are developed, approved, prescribed, monitored, and paid for. Each of these factors is discussed in this review.
Effectiveness of Childhood Obesity Treatment Through 20 Group Education Sessions Over 6 Months
Authors: Li Ming Wen
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Acute sport-related concussion suppresses heart rate variability beyond clinical recovery
Authors: Alexander D Wright, Jonathan D. Smirl, Harjas S. Grewal, Kelsey Bryk, Paul van Donkelaar
Journal: British Journal of Sports Medicine (2017)

Objective To examine the effect of acute sport-related concussion on heart rate variability (HRV) in contact-sport athletes over 1 month post-injury. Design Prospective Cohort. Setting Laboratory. Participants 136 male contact-sport athletes (19.1±1.4 years) were recruited and a subset of 14 athletes sustained concussions (19±1.4 years) and were included in the current analyses. Intervention Participants completed baseline (T0) and post-injury testing at 72-hours (T1), 2-weeks (T2), and 1-month (T3). A three-lead electrocardiogram was recorded to assess HRV during 5-minutes of quiet stance and while actively squatting at 0.10 Hz (6 squats per minute). Recordings were analysed using Kubios software (Kuopio, Finland). Independent variables included condition (resting versus active) and time (4). Outcome measures Time-Domain: square root of mean squared differences of successive R-R intervals (RMSSD), percentage of successive R-R intervals that differ by more than 50 milliseconds (pNN50). Non-linear: approximate entropy (ApEn). Main results RM-ANOVA revealed a significant main effect of time for ApEn only (p=0.016). ApEn was reduced at T2 (−0.126, 95% CI: 0.029–0.222, p=0.015) and T3 (−0.068, 95% CI: 0.009–0.128, p=0.027) compared to T0. Median return-to-play duration was 14.5 days. Conclusions Acute sport-related concussions induce a delayed reduction in heart rate variability that does not manifest until near-clinical recovery, and persists until at least 1-month post-injury. This is an important finding, indicating that concussions impair regulation of the autonomic nervous system for a duration persisting well beyond clinical recovery. Competing interests None.
Multi-disciplinary management of paediatricpediatric sports-related concussion: early experience of the pan am concussion program
Authors: Kelly Russell, Lesley Ritchie, Patrick J McDonald, Dean Cordingley, Karen Reimer, Richard Girardin, Sara Vis, Erin Selci, Peter MacDonald, Jeffrey Leiter, Michael Ellis
Journal: British Journal of Sports Medicine (2017)

Objective Summarise clinical characteristics, outcomes, and healthcare resources and personnel needs of paediatric sports-related concussion (SRC) patients who were evaluated and managed at a multi-disciplinary paediatric concussion program. Design Retrospective cohort study Setting Paediatric, multi-disciplinary concussion clinic Participants 423 paediatric SRC patients: 14.3 years (SD: 2.3), 59.6% males, 43.0% hockey-related, and 75.8% acute SRC Interventions (or assessment of risk factors) Initial assessment and diagnosis by a neurosurgeon with the multi-disciplinary team completing Return-to-Play decision-making. On-site neurosurgeon, neuropsychologist, vestibulo-ocular therapist, and exercise physiologist and referrals to neurology and psychiatry Outcome measures SRC diagnosis and recovery were defined by the 2013 Zurich Consensus Guidelines. Post-Concussion Syndrome was diagnosed using ICD-10 criteria of at least 3 symptoms at 30 days or more. Outcomes included demographic and injury data, healthcare resources and personnel utilised, and recovery Main results Overall, 294 (69.5%) of SRC patients met the clinical criteria for recovery, 75 (17.7%) were lost to follow-up, 53 (12.5%) remained in treatment, and 1 died (0.2%). In acute patients, median time to initial consultation was 7 days (IQR: 5, 12). Median days to recovery among acute SRC patients with complete follow-up was 23 days (IQR: 15, 36) and 44.1% of acute SRC patients were diagnosed with PCS. 25.3% of SRC patients underwent at least one diagnostic imaging test and 32.6% received referral to another member of our multi-disciplinary clinical team. Conclusions Youth received comprehensive care with access to appropriate diagnostic resources and multi-disciplinary collaboration of experts with national and provincially-recognised training in TBI Competing interests None.
Abstract 118: Role Of Histone Trimethyl Demethylase Jmjd2A In Cardiac Hypertrophy And Heart Development
Authors: Zhi-ping Liu, Qing-Jun Zhang
Journal: Circulation Research (2013)

Epigentic regulation via histone memethylation has been shown to play important role in embryonic development and pathogenesis of adult diseases. Methylation of histone H3 lysine 9 (H3K9) mediates heterochromatin formation and also participates in inhibition of gene transcription at euchromatic sites. Methylation of H3K9 is required for proper embryonic development as shown by various genetic studies of H3K9 methyltransferases in mice. Histone demethylases for methylated H3K9 have been shown to play important role in tumorigenesis. However, their roles in development and in adult cardiovascular diseases remain elusive. Jmjd2A is H3K9me3 specific demethylase. To study its biological functions, we generated mouse with conditional alleles of Jmjd2A. Our studies with post-natal heart specific Jmjd2A deletion and overexpression mouse lines indicated that Jmjd2A is required for pathological cardiac hypertrophy and the demethylase activity of Jmjd2A is required for its transcriptional activity. Jmjd2A also plays an important role during embryonic development. Mice with homozygous deletion of Jmjd2A exhibit partial embryonic lethality depending on the genetic background. In C57Bl6 (N&gt;5) mouse strain, some of the Jmjd2A-null embryos die between embryonic day E10-E12 with heart failure phenotype. Deletion of Jmjd2A appears to have no effect on formation of linear heart tube and subsequent looping at E9.5. However, while WT or Jmjd2A het hearts continue to grow with appearance of ventricular and atrial septum and formation of trabeculae, Jmjd2A-null embryonic hearts have pericardial effusion, thin myocardium, lack of atrial and ventricular septation, and under-developed trabaculae. These failing hearts show reduced cardiomyocyte proliferation. Gene expression profiling suggests potential downstream effectors of Jmjd2A including cell cycle and “immediate early” genes. Our data demonstrate that Jmjd2A plays important roles during heart development and functions as a hypertrophic determinant in response to pathological stimuli in adult hearts.
How functional are functional viewing fields?
Authors: Árni Kristjánsson, Andrey Chetverikov, Manje Brinkhuis
Journal: Behavioral and Brain Sciences (2017)

Abstract Hulleman &amp; Olivers' (H&amp;O's) proposal is a refreshing addition to the visual search literature. Although we like their proposal that fixations, not individual items should be considered a fundamental unit in visual search, we point out some unresolved problems that their account will have to solve. Additionally, we consider predictions that can be made from the account, in particular in relation to priming of visual search, finding that the account generates interesting testable predictions.
Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study
Authors: Gilles A. Salles, Judith Trotman, Michael Lill, Bruce Cheson, Stephen J. Schuster, Jing-Zhou Hou, John A Radford, Andrew Spencer, Michael Schaffer, Rajendra Damle, Gary J. Gartenberg, Jessica Vermeulen, Sriram Balasubramanian, Sanjay Deshpande, Dolores Caballero
Journal: Blood (2016)
Defining Treatment-Resistant Depression
Authors: David L. Fogelson, Andrew Leuchter
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Which do patients prefer as a first-line therapy, EGFR-TKI or chemotherapy, if they have NSCLC harboring EGFR mutation? A Vignettes study (LOGIK0903).
Authors: Jiichiro Sasaki, Shoji Tokunaga, Takayuki Suetsugu, Noriyuki Ebi, Minoru Fukuda, Nobuhiko Nagata, Koichi Takayama, Nobuko Tsuruta, Masayuki Ishida, Chinatsu Nishida, Kosuke Kashiwabara, Shinji Akamine, Kazutoshi Komiya, Noriaki Nakagaki, Hiroto Kishi, Takashi Seto, Sho Saeki, Yosuke Uchitomi, Yukito Ichinose
Journal: Journal of Clinical Oncology (2013)

e19016 Background: Treatment decision-making is associated with potential decisional conflict of patients. Aim of this study was to determine the preferences of advanced NSCLC patients for EGFR-TKI or chemotherapy as first-line therapy if they were in the situation of having a lung cancer harboring EGFR mutation, and to investigate the variables considered important to that preference. Methods: Three vignettes were designed to assess the patients’, the physicians’ or medical staff members’ preferences for treatment decision-making and the reasons classified into five category such as “evidence level”, “type of drug administration”, “therapeutic efficacy”, “adverse events”, and “influence to ordinary life” behind the decision. HADS, FACT-L and characteristics of participants including gender, age, and performance status (PS) are also investigated in this analysis. Results: Total 377 individuals containing 100 patients, 100 physicians, and 177 medical staff members were analyzed in this study, and 322 participants (85.4%) preferred to EGFR-TKI than chemotherapy as a first-line therapy. Preference rate of EGFR-TKI in patients was statistically significantly lower than those in physicians and medical staffs, 73%, 88% and 91%, respectively. Among the reasons we investigated, “therapeutic efficacy” was the only marginal significant reason for preference in patients (odds ratio: 3.88, p=0.06). In addition to “therapeutic efficacy”, “type of drug administration” and “influence to ordinary life” was the significant reasons for their preference in physicians (odds ratio: 11.57, 22.57 and 20.5, respectively). In pre-planned analysis, we found the difference of value between the patients and the physicians in “influence to ordinary life”. Conclusions: If the patients have an advanced lung cancer with EGFR mutation, they may prefer EGFR-TKI as a first-line therapy to chemotherapy as well as physicians and medical staff members. However the reasons of those preferences among them may be different. We should consider continuation of patients’ ordinary life when we discuss about treatment decision-making with patients. Clinical trial information: UMIN000003532.
Interventions to Reduce Postoperative Delirium
Authors: Pasithorn A. Suwanabol, Daniel B. Hinshaw
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Endoscopic full-thickness resection of a non-lifting large laterally spreading flat colonic polyp
Authors: Siddharth Javia, Bhavtosh Dedania, Xiaohang Wang, Shilpa Jain, Shashideep Singhal
Journal: Endoscopy (2017)

Resection of a non-lifting large laterally spreading flat colonic polyp can be challenging. A 44-year-old Hispanic woman with a history of hereditary non-polyposis colorectal cancer syndrome (HNPCC) was referred for removal of a laterally spreading polyp.
Prognostic value of epithelial cell adhesion molecule (EpCAM) in patients with primary epithelial ovarian cancer.
Authors: Hannah Woopen, Klaus Pietzner, Rolf Richter, Christina Fotopoulou, Thomas Joens, Ioana Braicu, Hakan Mellstedt, Silvia Darb-Esfahani, Carsten Denkert, Jalid Sehouli
Journal: Journal of Clinical Oncology (2012)

e15531 Background: EpCAM, a well known cancer antigene is currently experiencing a renaissance in its use as a binding site for targeted oncologic therapy and prognostic marker in various epithelial carcinomas such as breast cancer or carcinomas of the oral cavity. Goal of this retrospective study was to identify EpCAM as a potential prognostic marker for patients with primary epithelial ovarian cancer (EOC). Methods: EpCAM expression was assessed in tumor tissue by immunohistochemistry using the Avidin-Biotin-Complex method on paraffin-embedded ovarian cancer tissue samples. EpCAM overexpression was defined as an expression of EpCAM as high as 76-100%. Clinical data as well as tumor tissue samples were collected within the validated “Tumor bank Ovarian Cancer Network (TOC)”. Results: Seventy-four patients with the primary diagnosis of EOC between 01/1994 and 12/2009 were included in this study. Median age at diagnosis was 56 years. The vast majority of the patients (75.4%) presented an advanced stage disease (FIGO III/IV). Forty-one (55.4%) patients were diagnosed with a serous, 19 (25.6%) a endometrioid and 14 (19%) a mucinous histology. EpCAM was overexpressed in 87.7% of the patients. Serous tumors expressed EpCAM in significantly higher rates than mucinous tumors ( p=0.045). EpCAM overexpression correlated in univariate analysis with a significantly better overall survival. Multivariate analysis including histological subtype identified EpCAM expression of 76-100% to be independently associated with a significantly better overall survival compared to a lower EpCAM expression of ≤50% (p=0.008). Conclusions: EpCAM overexpression in EOC appears to be associated with significantly higher overall survival rates. Larger, prospectively assessed multicenter studies are warranted to further evaluate and confirm these novel findings and possibly establish EpCAM as a potent therapeutic target in EOC.